From the perspective of the clinical care of T2D patients who require intensified injection therapy, our findings are consistent with existing treatment guidelines [1, 3] and a real-world study [47], showing that using a GLP-1RA versus insulin therapy has therapeutic benefits in terms of reduced risks of hypoglycemia and all-cause death
Studies evaluate downstream effects on insulin receptor signaling, glucose transporter expression, and intracellular pathways involved in metabolic homeostasis
GLP-1 receptors are present not only in the pancreas and gastrointestinal tract but also in the central nervous system , including areas involved in taste perception and appetite regulation
Generally, BPC-157 is used for several weeks, with patients typically receiving treatment for 4 to 6 weeks after a bone injury or surgery
Some medications used along with tirzepatide may increase the risk of dizziness